(Q38378021)

2 September 2017

The preventive phase I trial with the HIV-1 Tat-based vaccine (English)

1 reference

2 September 2017

phase I clinical trial

0 references

17

Giuseppe Tambussi

1 reference

2 September 2017

Giovanni Paniccia

12

0 references

Stefania Bellino

Stefania Bellino

10

0 references

Alessandra Latini

Alessandra Latini

20

0 references

Fabrizio Ensoli

Fabrizio Ensoli

3

0 references

Massimo Giuliani

Massimo Giuliani

23

0 references

Aldo Di Carlo

Aldo Di Carlo

7

0 references

Paolo Monini

Paolo Monini

26

0 references

Barbara Ensoli

Barbara Ensoli

1

0 references

Adriano Lazzarin

Adriano Lazzarin

4

0 references

Andrea Antinori

21

Andrea Antinori

1 reference

2 September 2017

Valeria Fiorelli

2

1 reference

2 September 2017

Raffaele Visintini

5

1 reference

2 September 2017

Pasquale Narciso

6

1 reference

2 September 2017

Antonella Tripiciano

8

1 reference

2 September 2017

Olimpia Longo

9

1 reference

2 September 2017

Vittorio Francavilla

11

1 reference

2 September 2017

Angela Arancio

13

1 reference

2 September 2017

Arianna Scoglio

14

1 reference

2 September 2017

Barbara Collacchi

15

1 reference

2 September 2017

Maria Josè Ruiz Alvarez

16

1 reference

2 September 2017

Chiara Tassan Din

18

1 reference

2 September 2017

Guido Palamara

19

1 reference

2 September 2017

Gianpiero D'Offizi

22

1 reference

2 September 2017

Marina Giulianelli

24

1 reference

2 September 2017

Maria Carta

25

1 reference

2 September 2017

Mauro Magnani

27

1 reference

2 September 2017

Enrico Garaci

28

1 reference

2 September 2017

language of work or name

English

0 references

publication date

29 October 2009

1 reference

2 September 2017

1 reference

2 September 2017

28

1 reference

2 September 2017

2

1 reference

2 September 2017

371-378

1 reference

HIV vaccine design and the neutralizing antibody problem

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

HIV-1 Tat protein as a potential AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

The trans-activator gene of HTLV-III is essential for virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Quantifying the uncertainty in forecasts of anthropogenic climate change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Aluminium adjuvants--in retrospect and prospect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.10.038

1 reference

release_e33disivdjdfvcuzdo7hxnrxgm

2 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e33disivdjdfvcuzdo7hxnrxgm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference